$RGNX
REGENXBIO Inc.

2017 Q1 Form 10-Q Financial Statement

#000156459017009868 Filed on May 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $455.0K $393.0K
YoY Change 15.78% -38.98%
Cost Of Revenue $100.0K $30.00K
YoY Change 233.33% -9.09%
Gross Profit $400.0K $363.0K
YoY Change 10.19% -40.59%
Gross Profit Margin 87.91% 92.37%
Selling, General & Admin $6.600M $5.500M
YoY Change 20.0% 223.53%
% of Gross Profit 1650.0% 1515.15%
Research & Development $16.62M $6.183M
YoY Change 168.79% 121.53%
% of Gross Profit 4154.75% 1703.31%
Depreciation & Amortization $600.0K $0.00
YoY Change
% of Gross Profit 150.0% 0.0%
Operating Expenses $16.62M $6.183M
YoY Change 168.79% 121.53%
Operating Profit -$22.92M -$11.25M
YoY Change 103.73% 181.77%
Interest Expense $900.0K $500.0K
YoY Change 80.0% 2400.0%
% of Operating Profit
Other Income/Expense, Net $929.0K $483.0K
YoY Change 92.34% -2783.33%
Pretax Income -$22.00M -$10.80M
YoY Change 103.7% 170.0%
Income Tax
% Of Pretax Income
Net Earnings -$21.99M -$10.77M
YoY Change 104.24% 168.46%
Net Earnings / Revenue -4833.63% -2739.95%
Basic Earnings Per Share -$0.82
Diluted Earnings Per Share -$0.82 -$410.6K
COMMON SHARES
Basic Shares Outstanding 26.67M 26.33M
Diluted Shares Outstanding 26.67M

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.8M $101.1M
YoY Change 44.21% 298.03%
Cash & Equivalents $82.27M $35.51M
Short-Term Investments $63.80M $65.50M
Other Short-Term Assets $2.700M $2.500M
YoY Change 8.0% 2400.0%
Inventory
Prepaid Expenses
Receivables $200.0K $2.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $148.8M $105.6M
YoY Change 40.91% 294.03%
LONG-TERM ASSETS
Property, Plant & Equipment $11.10M $1.300M
YoY Change 753.85% 550.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $63.70M $107.9M
YoY Change -40.96% 35866.67%
Other Assets $500.0K $200.0K
YoY Change 150.0%
Total Long-Term Assets $75.30M $109.4M
YoY Change -31.17% 21780.0%
TOTAL ASSETS
Total Short-Term Assets $148.8M $105.6M
Total Long-Term Assets $75.30M $109.4M
Total Assets $224.1M $215.0M
YoY Change 4.23% 687.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.100M $1.100M
YoY Change 272.73% 37.5%
Accrued Expenses $5.800M $4.600M
YoY Change 26.09% 187.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.00M $5.781M
YoY Change 72.98% -18.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M $600.0K
YoY Change 116.67%
Total Long-Term Liabilities $1.300M $600.0K
YoY Change 116.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.00M $5.781M
Total Long-Term Liabilities $1.300M $600.0K
Total Liabilities $11.20M $6.383M
YoY Change 75.47% -10.1%
SHAREHOLDERS EQUITY
Retained Earnings -$62.39M
YoY Change
Common Stock $270.7M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $212.9M $208.6M
YoY Change
Total Liabilities & Shareholders Equity $224.1M $215.0M
YoY Change 4.24% 687.49%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$21.99M -$10.77M
YoY Change 104.24% 168.46%
Depreciation, Depletion And Amortization $600.0K $0.00
YoY Change
Cash From Operating Activities -$17.50M -$7.900M
YoY Change 121.52% 364.71%
INVESTING ACTIVITIES
Capital Expenditures $2.929M $416.0K
YoY Change 604.09% 292.45%
Acquisitions
YoY Change
Other Investing Activities $6.100M -$10.30M
YoY Change -159.22%
Cash From Investing Activities $3.200M -$10.70M
YoY Change -129.91% 10600.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $71.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 71.50M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -17.50M -7.900M
Cash From Investing Activities 3.200M -10.70M
Cash From Financing Activities 71.50M 0.000
Net Change In Cash 57.20M -18.60M
YoY Change -407.53% -176.86%
FREE CASH FLOW
Cash From Operating Activities -$17.50M -$7.900M
Capital Expenditures $2.929M $416.0K
Free Cash Flow -$20.43M -$8.316M
YoY Change 145.66% 360.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Revenues
Revenues
455000
CY2016Q1 us-gaap Revenues
Revenues
393000
CY2017Q1 us-gaap License Costs
LicenseCosts
91000
CY2016Q1 us-gaap License Costs
LicenseCosts
66000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16619000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6622000
CY2017Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-45000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
23377000
CY2017Q1 us-gaap Investment Income Net
InvestmentIncomeNet
929000
CY2016Q1 us-gaap Investment Income Net
InvestmentIncomeNet
483000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
929000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
483000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-21993000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-10768000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-539000
CY2016Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
994000
CY2017Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-539000
CY2016Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
994000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22532000
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9774000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21993000
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10768000
CY2016Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
59000
CY2016Q1 rgnx Grants Revenue Expenses
GrantsRevenueExpenses
6000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
30000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6183000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5479000
CY2016Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
114000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-471000
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
554000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
48000
CY2016Q1 us-gaap Costs And Expenses
CostsAndExpenses
11644000
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
480000
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-41000
CY2016Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
13000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-803000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22922000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11251000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.82
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26673000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26327000
CY2017Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
480000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2591000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1546000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-469000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-113000
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
68000
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
169000
CY2017Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-88000
CY2016Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
449000
CY2017Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000
CY2016Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
55000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
2468000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-182000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1920000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1210000
CY2016Q1 us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
-92000
CY2017Q1 rgnx Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
-44000
CY2016Q1 rgnx Increase Decrease In Deferred Rent Payable
IncreaseDecreaseInDeferredRentPayable
453000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17481000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7887000
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
5188000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20429000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
10500000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
780000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
416000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-10739000
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
147000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71299000
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
84000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
71523000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
21000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
57205000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-18605000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54116000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35511000
CY2017Q1 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
328000
CY2017Q1 rgnx Forfeiture Rate Used To Calculate Stock Based Compensation Expense
ForfeitureRateUsedToCalculateStockBasedCompensationExpense
0.00
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
127643000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
35000
CY2017Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
172000
CY2017Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
127506000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
133724000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
700000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
298000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
134126000
CY2017Q1 rgnx Available For Sale Securities Remaining Maturities Greater Than Three Years
AvailableForSaleSecuritiesRemainingMaturitiesGreaterThanThreeYears
0
CY2016Q4 rgnx Available For Sale Securities Remaining Maturities Greater Than Three Years
AvailableForSaleSecuritiesRemainingMaturitiesGreaterThanThreeYears
0
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-100000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
89900000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
102500000
CY2017Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2016 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
32
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
209551000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
158966000
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12239000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9948000
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1178000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
624000
CY2015Q3 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
300000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1199000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1638000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1686000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1605000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
665000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
952000
CY2017Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
7745000
CY2017Q1 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2017Q1 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2016 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2017Q1 rgnx Milestone Fee Payments Upon Submission Preclinical Filings
MilestoneFeePaymentsUponSubmissionPreclinicalFilings
500000
CY2017Q1 rgnx Milestone Fee Payments Upon Commencement Of Clinical Trials
MilestoneFeePaymentsUponCommencementOfClinicalTrials
24700000
CY2017Q1 rgnx Milestone Fee Payments Upon Submission Of Regulatory Approval Filings
MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings
40000000
CY2017Q1 rgnx Milestone Fee Payments Upon Approval Of Commercial Products
MilestoneFeePaymentsUponApprovalOfCommercialProducts
97500000
CY2017Q1 rgnx Milestone Fee Payments Upon Achievement Of Specified Sales Targets
MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets
92000000
CY2017Q1 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
250000
CY2016Q1 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
250000
CY2017Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
205000
CY2016Q1 us-gaap License And Services Revenue
LicenseAndServicesRevenue
78000
CY2017Q1 rgnx Licenses Revenue Including Amounts From Related Parties
LicensesRevenueIncludingAmountsFromRelatedParties
455000
CY2016Q1 rgnx Licenses Revenue Including Amounts From Related Parties
LicensesRevenueIncludingAmountsFromRelatedParties
328000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2591000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1546000
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
26200000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5780000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4718000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2965000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3338000
CY2017Q1 rgnx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
1586000
CY2016Q4 rgnx Accrued External Research And Development Expenses
AccruedExternalResearchAndDevelopmentExpenses
3005000
CY2017Q1 rgnx Accrued External General And Administrative Expenses
AccruedExternalGeneralAndAdministrativeExpenses
819000
CY2016Q4 rgnx Accrued External General And Administrative Expenses
AccruedExternalGeneralAndAdministrativeExpenses
672000
CY2017Q1 rgnx Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
129000
CY2016Q4 rgnx Accrued Purchases Of Property And Equipment
AccruedPurchasesOfPropertyAndEquipment
844000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
330000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
267000

Files In Submission

Name View Source Status
0001564590-17-009868-index-headers.html Edgar Link pending
0001564590-17-009868-index.html Edgar Link pending
0001564590-17-009868.txt Edgar Link pending
0001564590-17-009868-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rgnx-10q_20170331.htm Edgar Link pending
rgnx-20170331.xml Edgar Link completed
rgnx-20170331.xsd Edgar Link pending
rgnx-20170331_cal.xml Edgar Link unprocessable
rgnx-20170331_def.xml Edgar Link unprocessable
rgnx-20170331_lab.xml Edgar Link unprocessable
rgnx-20170331_pre.xml Edgar Link unprocessable
rgnx-ex101_117.htm Edgar Link pending
rgnx-ex311_120.htm Edgar Link pending
rgnx-ex312_118.htm Edgar Link pending
rgnx-ex321_119.htm Edgar Link pending
Show.js Edgar Link pending